RANCHO CORDOVA, Calif., Jan. 23, 2012 /PRNewswire/ -- ThermoGenesis Corp. (NASDAQ: KOOL), a leading supplier of innovative products and services that process and store adult stem cells, said today, it had received an initial order for its BioArchive® System from a new public cord blood bank that will begin operations in Canada in early 2013.
Canadian Blood Services, a national charitable organization that manages the supply of blood and blood products in all Canadian provinces and territories outside of Quebec, will begin collecting and storing umbilical cord blood stem cells in Ottawa, Ontario under its OneMatch Stem Cell and Marrow Network, effective April 1, 2013. Following the opening of this initial location, the organization plans to add three additional collection sites in Toronto, Ontario; Vancouver, British Columbia; and Edmonton, Alberta, as well as a second storage facility in Edmonton in 2014. This will represent the first national public cord blood bank in Canada.
The BioArchive System is an automated cryogenic device used by cord blood stem cell banks in more than 30 countries for cryopreserving and archiving cord blood stem cell units for transplant.
“We are very pleased to be working with Canadian Blood Services as they begin this highly worthwhile effort that will benefit all Canadians. The BioArchive has been the leading-edge technology for cord blood banks throughout the world for many years and we look forward to assisting in the roll out of this major program in Canada,” said J. Melville Engle, Chairman and Chief Executive Officer of ThermoGenesis.
“Given the growing use of stem cells to treat a wide variety of diseases, the creation of a national, public umbilical cord blood bank represents a much needed national healthcare resource that will provide life-saving treatments. The BioArchive represents best-in-class technology for the preservation and storage of stem cells from cord blood and it will be an integral part of our facilities’ infrastructure,” said Ian Mumford, Chief Operating Officer of Canadian Blood Services.
About Canadian Blood Services
Canadian Blood Services is a national, not-for-profit charitable organization that manages the supply of blood and blood products in all Canadian provinces and territories outside of Quebec. Canadian Blood Services also oversees the OneMatch Stem Cell and Marrow Network, and provides national leadership for organ and tissue donation and transplantation. Canadian Blood Services operates 43 permanent collection sites and more than 20,000 donor clinics annually. The provincial and territorial Ministries of Health provide operational funding to Canadian Blood Services. The federal government, through Health Canada, is responsible for regulating the blood system. For more information, please visit our website, www.blood.ca.
About ThermoGenesis Corp.
ThermoGenesis Corp. (www.thermogenesis.com) is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products. These include:
- The BioArchive® System, an automated cryogenic device, used by cord blood stem cell banks in more than 30 countries for cryopreserving and archiving cord blood stem cell units for transplant.
- AXP® AutoXpress® Platform (AXP), a proprietary family of automated devices that includes the AXP and the MXP® MarrowXpress® and companion sterile blood processing disposables for harvesting stem cells in closed systems. The AXP device is used for the processing of cord blood. The MXP is used for the preparation of cell concentrates, including stem cells, from bone marrow aspirates in the laboratory setting.
- The Res-Q® 60 BMC/PRP (Res-Q), a point-of-care system designed for the preparation of cell concentrates, including stem cells, from bone marrow aspirates and whole blood for platelet rich plasma (PRP).
- The CryoSeal® FS System, an automated device and companion sterile blood processing disposable, used to prepare fibrin sealants from plasma in about an hour. The CryoSeal FS System is approved in the U.S. for liver resection surgeries. The CryoSeal FS System has received the CE-Mark which allows sales of the product throughout the European community.
This press release contains forward-looking statements. These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors including timing of FDA and foreign regulatory approvals, changes in customer forecasts, our failure to meet customers’ purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers’ products, introduction timing and acceptance of our new products scheduled for fiscal year 2012, and introduction of competitive products and other factors beyond our control could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2012. A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption “Risk Factors” in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.
ThermoGenesis Corp.
Web site: http://www.thermogenesis.com
Contact: Investor Relations
+1-916-858-5107, or
ir@thermogenesis.com
SOURCE ThermoGenesis Corp.
